tradingkey.logo

BRIEF-Allogene Therapeutics Announces Publication Of Durable Response Data From Phase 1 Alpha/Alpha2 Trials Of The Allogeneic Car T Cemacabtagene Ansegedleucel/Allo-501

ReutersFeb 13, 2025 10:15 PM

- Allogene Therapeutics Inc ALLO.O:

  • ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY

  • ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY

Source text: ID:nGNX75ZxGV

Further company coverage: ALLO.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI